21196229-e39e-4846-be58-a1055b3ae50e
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 55
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.560
- HEDGEHOG_SIGNALING+0.500
- TNFA_SIGNALING_VIA_NFKB+0.440
- APICAL_JUNCTION+0.400
- UV_RESPONSE_DN+0.400
- INFLAMMATORY_RESPONSE+0.370
- KRAS_SIGNALING_UP+0.370
- COAGULATION+0.350
- MYOGENESIS+0.350
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.650
- MYC_TARGETS_V2-0.630
- MYC_TARGETS_V1-0.590
- E2F_TARGETS-0.460
- DNA_REPAIR-0.440
- FATTY_ACID_METABOLISM-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- ADIPOGENESIS-0.320
- G2M_CHECKPOINT-0.310
- MTORC1_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.960 |
| 2 | 4f709f4b-3140-47be-b55a-7713062545e9 | — | — | 0.948 |
| 3 | 67ed15bc-bbe5-4da7-81f9-002c54483f67 | — | — | 0.945 |
| 4 | 94f6e4f5-2447-4f1f-9f36-411f1c25a172 | — | — | 0.940 |
| 5 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.939 |
| 6 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.934 |
| 7 | 1b5aacb8-0e2e-4888-bc61-48c4aa4d4684 | — | — | 0.934 |
| 8 | TCGA-CX-7085-01A-21R-2016-07 | — | — | 0.927 |
| 9 | 4925248f-21e2-476e-937c-02e0a748c77b | — | — | 0.925 |
| 10 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.560 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |